Utah Medical Products (NASDAQ:UTMD) Stock Price Passes Above 200 Day Moving Average – What’s Next?

Utah Medical Products, Inc. (NASDAQ:UTMD)’s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $59.61 and traded as high as $68.71. Utah Medical Products shares last traded at $67.82, with a volume of 87,162 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of Utah Medical Products in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Utah Medical Products presently has an average rating of “Sell”.

Utah Medical Products Price Performance

The firm has a 50-day simple moving average of $60.35 and a 200 day simple moving average of $59.61. The stock has a market capitalization of $217.02 million, a P/E ratio of 19.49 and a beta of 0.34.

Utah Medical Products (NASDAQ:UTMD) last released its quarterly earnings data on Thursday, January 29th. The medical instruments supplier reported $0.80 earnings per share (EPS) for the quarter. Utah Medical Products had a return on equity of 9.60% and a net margin of 29.30%.The company had revenue of $9.04 million during the quarter.

Utah Medical Products Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 3rd. Stockholders of record on Tuesday, March 17th will be paid a dividend of $0.31 per share. The ex-dividend date of this dividend is Tuesday, March 17th. This represents a $1.24 annualized dividend and a dividend yield of 1.8%. Utah Medical Products’s dividend payout ratio (DPR) is presently 35.63%.

Institutional Trading of Utah Medical Products

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brandes Investment Partners LP lifted its holdings in Utah Medical Products by 4.0% during the 4th quarter. Brandes Investment Partners LP now owns 351,322 shares of the medical instruments supplier’s stock worth $19,660,000 after buying an additional 13,392 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Utah Medical Products by 1.3% during the third quarter. Dimensional Fund Advisors LP now owns 200,032 shares of the medical instruments supplier’s stock worth $12,596,000 after acquiring an additional 2,566 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Utah Medical Products by 6.5% during the second quarter. Geode Capital Management LLC now owns 114,816 shares of the medical instruments supplier’s stock worth $6,537,000 after acquiring an additional 7,040 shares during the last quarter. Minerva Advisors LLC lifted its stake in shares of Utah Medical Products by 0.6% in the fourth quarter. Minerva Advisors LLC now owns 93,615 shares of the medical instruments supplier’s stock worth $5,239,000 after acquiring an additional 557 shares during the period. Finally, Rice Hall James & Associates LLC boosted its holdings in Utah Medical Products by 4.8% in the fourth quarter. Rice Hall James & Associates LLC now owns 64,398 shares of the medical instruments supplier’s stock valued at $3,604,000 after acquiring an additional 2,967 shares during the last quarter. 69.60% of the stock is currently owned by institutional investors and hedge funds.

Utah Medical Products Company Profile

Utah Medical Products, Inc (NASDAQ: UTMD), headquartered in Midvale, Utah, is a designer, manufacturer and marketer of single‐use medical devices focusing principally on respiratory therapy and patient monitoring applications. Since its founding in the late 1970s, the company has built a reputation for innovation in airway management and non‐invasive monitoring products used in acute and long‐term care settings.

The company’s core product portfolio includes tracheostomy tubes and related accessories, endotracheal tube holders, disposable catheters and sensors for measuring end‐tidal carbon dioxide (CO₂).